LATEST NEWS
  •  
    Express Scripts touts a 'fundamental change' in drug pricing; others would call it negotiating a discount
    Throughout 2014, Gilead Science's Sovaldi treatment for hepC--the first drug that is an outright cure for the disease in many cases--has attracted extraordinary attention. Its high price (about $84K for a 12-week regimen) is not the highest among specialty pharmaceutical therapies; and the cohort of patients--an estimated 3.2 million in the US--is also not extraordinary compared to other debilitating conditions. But the combination of those two factors, its clear advantage over prior therapies and the estimated $8.7 billion it garnered for Gilead through the first 10 months on the market has made it a stalking horse
  •  
    'Stay tuned' for interactions directly with pharma companies, says CEO Jeff Tangney
    Nestled in the high-tech Silicon Valley area, Doximity has positioned itself as a state-of-the-art, social-media-driven community, but one dedicated exclusively to physicians. The company has announced that its signed-on membership among physicians is now over 400,000, representing roughly half of all prescribing physicians in the US. In the intense battle for attention and interaction with physicians, in which pharma companies touting their products compete with healthcare providers, professional and personal interests and all the other things that physicians can look at
  •  
    Global market will rise 30% over the next five years, reaching $1.3 trillion
    The go-go days of the early 2000s, when the US pharma industry routinely had double-digit growth, haven't exactly returned in full force. But from the 1-3% annual increases in the past several years--including a first-in-recent-history actual decline in 2012--the US market is projected to grow 11-13% when the books close on 2014. The "official" count, from IMS Health, won't be ready until early spring 2015, but in its annual "Global Use of Medicines" report, just issued, IMS' Institute for Healthcare Informatics projects that the US market will be in the range of $377-384 billion for 2014, up 11-13%. It and Japan will experience a "spike" in 2014-5; after that growth
  •  
    Envoy Direct is tailored to direct-to-patient shipments
    Several major air carriers and express delivery services have announced plans beginning in 2015 to bill shippers for the "dimensional weight" of their packages, which takes into account the size of the package as well as its weight. To meet optimal cost and shipping factors like this, Sonoco ThermoSafe (Arlington Heights, IL) is now marketing the Envoy Direct series of temperature-controlled packaging. Specialty pharmacies, mail order and similar drug dispensers can use the packages to make cost-effective deliveries to the patient's home, for example
  •  
    'Exception handling' will be the monkey wrench in maintaining normal distribution
    You heard it was coming, and now it's almost here: the Jan. 1 deadline, per the Drug Supply Chain Security Act (DSCSA), for pharma trading partners to receive lot-level transaction information as products are delivered to them. At the HDMA Traceability Seminar (Nov. 10-12, Arlington, VA), wholesaler representatives talked about anticipated situations come Jan. 1; they also heard, from Dr. Connie Jung, RPh, acting associate director at the Office of Drug Security, Integrity and Recalls of FDA, that the Nov. 27 deadline FDA has for providing guidance based on DSCSA will be delivered (but probably not before that date). That leaves the US pharma
  •  
    Action occurs as parent Publicis Groupe acquires leading digital agency, Sapient
    Rick Keefer, president and CEO of Publicis Touchpoint Solutions (Yardley, PA) has been promoted to the title of global chief business development officer for Touchpoint's parent, Publicis Healthcare Communications, which claims the label of "the world's largest health-oriented communications network." And that positioning might be about to grow larger as the global parent, Paris-based Publicis Groupe, announced the $3.7-billion acquisition of Sapient, an IT and consulting company deeply embedded in online business/customer interactions, from e-commerce to marketing services. Michelle Keefe, COO at Touchpoint for the past three years, has been promoted
  •  
    More engagement with pharma financial, marketing and supply-chain teams calls for easier access, says the company
    "Channel data"--the information on how product inventories are maintained at wholesalers, retailers and elsewhere--used to be the exclusive purview of trade relations managers at pharma companies. But as the drive toward better market signal sensing, lower inventory levels and better forecasting has been accepted by the pharma industry, these data are of value to more parts of the companies. Through use of electronic data interchange (EDI), it is now possible to get an accurate fix of product movement on a daily basis, at least
  •  
    Regulatory compliance continues to exceed cost as a primary driver
    UPS' seventh global survey of supply chain managers in healthcare products finds a greater consensus of industry goals regarding supply chain management, but a lesser degree of actually following through on those goals. All this is occurring in a context of rapid change, driven by the desire to tap into global markets, adoption of new distribution channels, and the urgency to keep up with expanding regulatory compliance initiatives. "One of the values of this survey is the timeline it establishes for industry issues," notes John Menna, VP for healthcare strategy. "In past years, we've asked about global initiatives and found that 81% of healthcare executives planned
  •  
    Pharmaceutical Commerce's latest report finds continued growth in these specialized logistics services
    The 5th edition of the Biopharma Cold Chain Sourcebook analyzes economic, regulatory and technological trends in a vital part of today's industry: the shipment of temperature-controlled products. The just-published report calculates that current (2014) expenditures for commercial shipments will be $8.36 billion, rising to $10.28 billion in 2018. By comparison, last year's Sourcebook estimated the 2013 cold-chain business to be $7.5 billion, rising
Pharmaceutical Commerce
Digital Edition
Current Digital Edition
Read the November/December 2014 Issue now - It's Free!
COLD CHAIN FOCUS
Cargo, logistics and packaging interests are represented
 
INDUSTRY EVENTS
 
 
 
 
WHAT THEY'RE SAYING
Homi Kapadia was appointed head of the Life Sciences Practice last June. He sat down with Pharmaceutical Commerce this summer to talk about trends in life sciences, new initiatives in Deloitte and his evolving role. Here’s what he had to say.
 
 
FEATURES
In the past five years, the role of Master Data Management (MDM) and informatics has dramatically changed the strategic and operational objectives of life sciences organizations  continued >
 
Service providers are building out a wider range of services to meet drug developers' needs  continued >
 
More complex products and higher risk are changing the nature of pharmaceutical outsourcing  continued >
 
As rare diseases have emerged as a market opportunity for pharma over the past several years, industry practices are beginning to stabilize  continued >
 
The drive for lower costs, safer products  continued >
 
 
MOST POPULAR STORIES
 
 
SPECIAL FOCUS REPORT
2014 Cold Chain Directory
 
Our annual compilation of key vendors and service providers in this vital component of pharmaceutical distribution, together with a preview of the IQPC Cold Chain Forum and more late-breaking news
 
CLINICAL OPERATIONS
LabCorp’s $6.1-billion bid for leading CRO has implications for pharma’s future
 
 
 
   
  |     |     |     |     |     |  
©2014 Pharmaceutical Commerce. All Rights Reserved.  |  Website managed and designed by Offenberger & White.